Medicus Pharma provides interpretation of Phase 2 SkinJect dataset

Medicus Pharma (MDCX) provided additional context regarding the recently reported topline dataset from the Phase 2 SKNJCT-003 study evaluating SkinJect microneedle delivery of D-MNA and P-MNA for basal cell carcinoma, BCC. The dataset demonstrated 73% clinical clearance and 40% histological clearance in the 200-microgram treatment cohort at Day 57, representing the strongest treatment response observed in the study. “We believe that these findings are particularly notable given the device-based mechanism of SkinJect, where microneedle delivery itself may produce biological activity that can contribute to responses observed even in placebo active arm, that was not tip-loaded with the chemotherapeutic agent,” the company said.